



Comprehensive Cancer Care and Research Network:
the IRST- AUSL Romagna Strategy to Fight Cancer

20-21-22 settembre 2022

Auditorium San Giacomo, Piazza Guido da Montefeltro, Forlì



Giovanni Martinelli,
Scientific Director
IRCCS-IRST Istituto Tumori della Romagna



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI


DAL 2017 al 2021: CONFRONTO SU PERFORMANCE E DIMENSIONI



Ministero della Salute

Direzione Generale della Ricerca e dell'Innovazione in Sanità

Ricerca Corrente 2019



Comprehensive Cancer Care Network della Romagna



L'IRST ed il CCRN di DOMANI - ANNO 2022-26

Piattaforme logistiche integrate tra Azienda USL della Romagna e IRST per attività assistenziale e di ricerca



***Ospedale Santa Maria delle Croci
Ravenna***



***Ospedale M. Bufalini
Cesena***



***Ospedale Morgagni Pierantoni
Forlì***



Ospedale Infermi Rimini

L'IRST ed il CCRN DOMANI - ANNO 2022-2026

Sviluppo della medicina personalizzata: Identificazione di target molecolari

PRECISION TARGETING TO ERADICATE CANCER


Aiming to help patients with cancer through the discovery and development of novel targeted therapeutics with curative potential.



Sequenziatore Termofisher




**Nanostring GEO MIX 3 D
spatial resolution**




NovaSeq 6000


ONE CELL. MANY FATES.



**Piattaforma di sviluppo per attività di ricerca per terapie
cellulari somatiche ingegnerizzate e non
NK - CarT- Dendritic Cell – antiCancer Vaccine**




ISTITUTO
SCIENTIFICO
ROMAGNOLI
PER LO STUDIO E LA CURA
DEI TUMORI





lo complementare
PNRR




Antibody
Engineering



Research project on CAR T cells for hematological malignancies and solid tumors

*Conducted under the aegis of Alliance Against Cancer (AAC) network
Project coordinator: Prof. Franco Locatelli*



Dendritic cells

T cells

$\gamma\delta$ T cells

B cells

NK cells

Macrophage Cells

Production Ingengerized- T at IRST




ISTITUT
SCIENTIFIC
ROMAGNOL
PER LO STUDI E LA CURA
DEI TUMORI

DIGITAL PATHOLOGY

An Introduction to Spatial Biology and Spatial Profiling

ISTITUT
SCIENTIFIC
ROMAGNOL
PER LO STUDI E LA CURA
DEI TUMORI




RADIOMICA e TERANOSTICA



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
SCIENTIFICO
ROMAGNOLO
PER LO STUDIO E LA CURA
DEI TUMORI

Il Progetto IRST CCNR Radiomics



IL Database del SAPERE dell'IRST




ORIGIN

PART 
PROTEOMIC FACILITY IRST


ALiCE

CONSORZIO IRCCS DELLA GENOMICA INNOV

DATA ANALYSIS E DATA SHARING FACILITIES



HUMAN AVATAR



Ministero della Salute

Direzione generale della ricerca e dell'innovazione in sanità

PNRR: M6/C2_CALL 2022 Full Proposal



Finanziato
dall'Unione europea
NextGenerationEU

Project Code: PNRR-POC-2022-12375862

Call section: Proof of concept **Simonetti Giorgia, Ferrari Anna**

Applicant Institution: Istituto scientifico romagnolo per
lo studio e la cura dei tumori

Applicant/PI Coordinator: Martinelli Giovanni



Evaluation of rare fusions in Philadelphia positive Acute Lymphoblastic Leukemia (ALL) samples

Finanziamento complessivo € 1.000.000

Finanziamento per IRST € 60%

Durata 2 anni



Ministero della Salute

Direzione generale della ricerca e dell'innovazione in sanità

PNRR: M6/C2_CALL 2022 Full Proposal



Finanziato
dall'Unione europea
NextGenerationEU


Project Code: PNRR-POC-2022-12376586

Call section: Proof of concept

Fabbri Francesco

Applicant Institution: Istituto scientifico romagnolo per
lo studio e la cura dei tumori

Applicant/PI Coordinator: Ulivi Paola



Finanziamento complessivo € 1.000.000

Finanziamento per IRST € 60%

Durata 2 anni

Call: HORIZON-CL3-2021-CS-01


(Increased cybersecurity 2021)

Proposal acronym: TRUMPET

PI Giovanni Martinelli



 Ref. Ares(2021)7262813 - 25/11/2021



TRUstworthy Multi-site Privacy Enhancing Technologies

Proposal for HORIZON-CL3-2021-CS-01-04 topic

Quota IRST € **550.000**

Durata 3 anni

6	TECHNOVATIVE SOLUTIONS LTD	UK
7	TIME.LEX	BE
8	CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE	BE
9	COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES	France



Workshop CCCRN-IRST

Metabolism of Leukemia: Role of PRMT5 and MAT inhibitors on LSC Apoptosis

March 06-07, 2023

Virtual Meeting

PROGRAM

Please Note: All session times for the CCNR Virtual Meeting.

Chair:

Giovanni Martinelli, Gerardo Musuraca

Co Chair:

Giovanni Marconi,

Cristina Papayannidis*, Claudio Cerchione, Giorgia Simonetti, Alessandro Lucchesi, Angelo del Monte.

November
7-8, 2022

Workshop CCCRN-IRST-SohoIT

Novel Menin-MLL Inhibitors

**Target MLL-Rearranged
Leukemia**

November 7 and 8, 2022


Virtual Meeting



M-525

NOW/SOON ENROLLING AT IRST


is a First-in-class,
Irreversible and
Covalent Menin-MLL
Protein-Protein Interaction
Inhibitor



SNDX-5613

NOW/SOON ENROLLING AT IRST


is a Potent and
Specific Menin-MLL Inhibitor




KOMET-001: A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (KO-MEN-001)



Fig. 3. Schematic representation of typical, oncogenic KMT2A (= MLL1) fusion proteins





Grazie

per l'attenzione

ISTITUT
ROMAGNOL
PER LO STUDIO
DEI TUMORI
DINO AMADORI

SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico